For motion sickness, how do diphenhydramine (Benadryl) and dimenhydrinate (Dramamine) compare in terms of dosing, efficacy, and side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dimenhydrinate vs Diphenhydramine for Motion Sickness

For motion sickness prevention, dimenhydrinate (Dramamine) is the preferred first-generation antihistamine based on FDA approval and specific dosing guidance for this indication, though both agents have comparable efficacy and side effect profiles.

Dosing

Dimenhydrinate (Dramamine)

  • Adults and children ≥12 years: 50-100 mg every 4-6 hours (maximum 400 mg/24 hours)
  • Children 6 to <12 years: 25-50 mg every 6-8 hours (maximum 150 mg/24 hours)
  • Children 2 to <6 years: 12.5-25 mg every 6-8 hours (maximum 75 mg/24 hours)
  • Timing: Take first dose 30-60 minutes before travel 1

Diphenhydramine (Benadryl)

  • Adults: 25-50 mg every 4-6 hours (maximum 300 mg/24 hours)
  • Timing: Several minutes onset, 4-6 hour duration 2, 3
  • Note: Diphenhydramine lacks specific FDA labeling for motion sickness, though it has antihistaminic and anticholinergic properties similar to dimenhydrinate

Efficacy

Both agents are effective for motion sickness prevention under natural conditions. A 2022 Cochrane review found that first-generation antihistamines (including dimenhydrinate) prevented motion sickness symptoms in 40% of susceptible individuals versus 25% with placebo (RR 1.81,95% CI 1.23-2.66; moderate-certainty evidence) 4.

Dimenhydrinate specifically has been shown to:

  • Reduce motion sickness symptom scores by an average of 5.9 points compared to placebo (p<0.001) 5
  • Suppress gastric tachyarrhythmia associated with motion sickness 5
  • Prevent development of abnormal gastric myoelectric activity during motion exposure 5

There are no head-to-head trials directly comparing diphenhydramine to dimenhydrinate for motion sickness. Both work through H1-receptor antagonism and anticholinergic effects 2, 6, 7.

Side Effects

Common to Both Agents

  • Sedation: Most significant adverse effect. Antihistamines may cause sedation in 66% of users versus 44% with placebo (RR 1.51,95% CI 1.12-2.02) 4
  • Anticholinergic effects: Dry mouth, blurred vision (14% vs 12.5% placebo), urinary retention, constipation 2, 3
  • CNS effects: Dizziness, impaired cognition (though not significantly different from placebo at 29% vs 33%) 2, 4
  • Cardiovascular: Hypotension 2, 3

Critical Performance Impairment Concerns

Dimenhydrinate causes significant psychomotor impairment. A 2001 study found that dimenhydrinate 100 mg significantly impaired decision reaction time and auditory digit span, with most subjects reporting decreased well-being and general performance abilities 8. This impairment can occur without subjective awareness of drowsiness 9.

Warning: First-generation antihistamines are associated with 1.5-fold increased risk of fatal automobile accidents and increased occupational accidents 9. Performance impairment persists beyond plasma half-life due to prolonged end-organ effects 9.

Formulation Differences

Slow-release formulations of dimenhydrinate (chewing gums with divided dosing) produce less sedation and CNS impairment than standard tablets while maintaining efficacy, likely due to slower CNS drug accumulation 10.

Clinical Algorithm

Step 1: Assess patient factors

  • Age (children require weight-based dosing)
  • Need for alertness (driving, operating machinery)
  • Duration of travel
  • Pregnancy status (both Category B, but avoid first trimester)

Step 2: Choose agent

  • Dimenhydrinate: First choice due to FDA approval for motion sickness with clear dosing guidelines 1
  • Diphenhydramine: Reasonable alternative if dimenhydrinate unavailable, using similar dosing

Step 3: Timing and administration

  • Administer 30-60 minutes before motion exposure 1
  • For prolonged travel, redose per schedule above
  • Consider slow-release formulations if available to reduce sedation 10

Step 4: Counsel on safety

  • Do not drive or operate machinery after taking either medication
  • Avoid alcohol and other CNS depressants 2, 9
  • Expect sedation even if not subjectively drowsy 9
  • Watch for anticholinergic effects (dry mouth, urinary retention)

Important Caveats

  • Neither agent should be used routinely for vertigo from other causes (e.g., BPPV), where repositioning maneuvers are superior 6
  • Chronic high-dose use of dimenhydrinate has been associated with cognitive impairment and should be avoided 11
  • Scopolamine may be superior for severe motion sickness, though comparison data are limited (very low-certainty evidence) 4
  • No evidence supports use in children <2 years for dimenhydrinate 1
  • Both agents work through similar mechanisms (H1-antagonism and anticholinergic effects), so switching between them is unlikely to improve efficacy or reduce side effects 12, 7

References

Guideline

aga institute review of endoscopic sedation.

Gastroenterology, 2007

Research

Antihistamines for motion sickness.

The Cochrane database of systematic reviews, 2022

Guideline

clinical practice guideline: benign paroxysmal positional vertigo.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008

Research

The Neurophysiology and Treatment of Motion Sickness.

Deutsches Arzteblatt international, 2018

Research

The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.

Journal of psychopharmacology (Oxford, England), 2001

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Related Questions

Can a patient using a 1.5 mg scopolamine transdermal patch for motion sickness safely take diphenhydramine (25–50 mg oral) concurrently?
What are the differences between hydroxyzine and cinnarizine for the prevention and treatment of motion sickness?
What are the current indications and dosing updates for dimenhydrinate (Dimenhydrinate)?
Is 100mg of dimenhydrinate (Dramamine) a safe dose for a 50kg adult patient with motion sickness?
What is the recommended dosage of Dramamine (dimenhydrinate) for a 22-month-old child with motion sickness?
Can mirtazapine be used as a single agent after stopping quetiapine to manage insomnia and depression in an adolescent?
What are the contraindications for indocyanine green (ICG)?
What are the classifications of parathyroid gland positions, including normal superior and inferior locations and ectopic sites?
Can Wernicke's encephalopathy still be diagnosed in a patient who has been sober for 12 years but was a heavy drinker previously?
In a 4-year-old child with dark circles, daytime irritability, and imaging showing severely enlarged adenoids and palatine tonsils occluding the nasopharyngeal airway, what is the likely diagnosis and recommended treatment?
In a 5‑year‑old child (~40 lb) with grade‑3 tonsillar size, normal‑appearing tonsils on ENT exam but lateral neck X‑ray showing airway narrowing, loud snoring, nasal speech, dark circles, and marked irritability, should we obtain an overnight polysomnography before deciding on adenotonsillectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.